Royalty Pharma PLC $RPRX Stock Purchased by Vise Technologies Inc.

Vise Technologies Inc. lifted its stake in Royalty Pharma PLC (NASDAQ:RPRX) by 35.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 32,473 shares of the biopharmaceutical company’s stock after acquiring an additional 8,515 shares during the period. Vise Technologies Inc.’s holdings in Royalty Pharma were worth $1,895,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in RPRX. Glenmede Trust Co. NA boosted its stake in shares of Royalty Pharma by 3.4% during the 1st quarter. Glenmede Trust Co. NA now owns 7,812 shares of the biopharmaceutical company’s stock valued at $375,000 after buying an additional 254 shares during the period. MBL Wealth LLC increased its stake in shares of Royalty Pharma by 7.3% in the third quarter. MBL Wealth LLC now owns 3,908 shares of the biopharmaceutical company’s stock worth $228,000 after acquiring an additional 266 shares during the last quarter. Bessemer Group Inc. increased its stake in shares of Royalty Pharma by 34.7% in the first quarter. Bessemer Group Inc. now owns 1,094 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 282 shares during the last quarter. CoreCap Advisors LLC increased its stake in shares of Royalty Pharma by 89.2% in the second quarter. CoreCap Advisors LLC now owns 876 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 413 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC raised its holdings in shares of Royalty Pharma by 1.7% during the first quarter. Allspring Global Investments Holdings LLC now owns 27,228 shares of the biopharmaceutical company’s stock worth $1,329,000 after acquiring an additional 454 shares in the last quarter. 54.35% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Royalty Pharma

In related news, EVP Christopher Hite sold 100,000 shares of the company’s stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $58.53, for a total value of $5,853,000.00. Following the completion of the sale, the executive vice president owned 270,401 shares in the company, valued at $15,826,570.53. This represents a 27.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 4,126 shares of Royalty Pharma stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $57.10, for a total value of $235,594.60. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 208,252 shares of company stock valued at $12,324,407 in the last three months. 18.84% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on RPRX. Morgan Stanley raised their price target on Royalty Pharma from $65.00 to $67.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. Bank of America reiterated a “buy” rating on shares of Royalty Pharma in a report on Wednesday, August 5th. The Goldman Sachs Group reissued a “buy” rating and issued a $66.00 price target on shares of Royalty Pharma in a research note on Thursday, August 6th. Weiss Ratings upgraded Royalty Pharma from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday, September 14th. Finally, TD Cowen increased their price objective on Royalty Pharma from $65.00 to $68.00 and gave the stock a “buy” rating in a report on Tuesday, September 8th. Eight investment analysts have rated the stock with a Buy rating. Based on data from MarketBeat.com, Royalty Pharma presently has an average rating of “Buy” and an average target price of $63.29.

Key Headlines Impacting Royalty Pharma

Here are the key news stories impacting Royalty Pharma this week:

• Positive Sentiment: Citigroup raised its price target to $78 from $70 and reiterated a Buy rating, citing potential upside from the current share price. TickerReport article
• Positive Sentiment: Royalty Pharma raised its 2026 royalty-receipts outlook to $3.55 billion. The improved forecast may support expectations for continued business growth. RTTNews article
• Positive Sentiment: On an adjusted basis, third-quarter EPS was reported at $1.21, ahead of the $1.18 consensus estimate and up from $1.17 a year earlier. Zacks also reported revenue above its estimate. Zacks article
• Neutral Sentiment: Published earnings summaries show different figures for EPS and revenue, reflecting differing measures or estimates. Investors should distinguish adjusted results from GAAP results when assessing the quarter. Business Insider results
• Negative Sentiment: One report put GAAP EPS at $0.32, below the $1.18 consensus, and revenue at $690.1 million versus an $884.8 million estimate. That reported shortfall could temper optimism about the adjusted earnings beat. MarketBeat earnings report

Royalty Pharma Price Performance

Royalty Pharma stock opened at $67.57 on Friday. The business has a 50 day simple moving average of $60.71 and a 200 day simple moving average of $53.67. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.80 and a quick ratio of 2.80. The company has a market capitalization of $38.85 billion, a PE ratio of 56.31, a price-to-earnings-growth ratio of 1.85 and a beta of 0.37. Royalty Pharma PLC has a one year low of $37.31 and a one year high of $69.77.

Royalty Pharma (NASDAQ:RPRX) last issued its earnings results on Wednesday, August 5th. The biopharmaceutical company reported $1.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.27 by $0.05. The firm had revenue of $674.14 million for the quarter, compared to analysts’ expectations of $758.93 million. Royalty Pharma had a return on equity of 30.02% and a net margin of 25.68%. On average, sell-side analysts forecast that Royalty Pharma PLC will post 5.29 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be issued a $0.2350 dividend. The ex-dividend date of this dividend is Friday, November 13th. This represents a $0.94 annualized dividend and a dividend yield of 1.4%. Royalty Pharma’s payout ratio is 78.33%.

Royalty Pharma Company Profile

Royalty Pharma plc (NASDAQ:RPRX) is a biopharmaceutical royalty investment company that provides funding to life sciences companies, academic institutions, and other organizations in exchange for rights to future payments tied to approved or development-stage medicines. Its business model gives innovators access to capital while allowing Royalty Pharma to participate in the long-term commercial success of pharmaceutical products.

The company acquires and manages royalty interests across a broad range of therapeutic areas, including immunology, oncology, neuroscience, rare diseases, and infectious diseases.